Revenue growth isn't explosive, but it's steady because of BWX's nuclear moat.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
Apenas manchetes de alto sinal — eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
Revenue growth isn't explosive, but it's steady because of BWX's nuclear moat.
The SpaceX IPO is garnering huge attention worldwide.
When considering Oklo and Uranium Energy this year, investors may do well to not fight the tape.
With an upside potential of 24.9%, Oklo Inc. (NYSE:OKLO) earns a spot on our list of the best nuclear energy stocks to buy as SMRs go mainstream. Oklo Inc. (NYSE:OKLO) received a meaningful regulatory de-risking boost on May 6, 2026, when the NRC approved its Principal Design Criteria (PDC) topical report for the Aurora powerhouse […]
A company with $503,000 in quarterly revenue is worth nearly $3 billion.
The S&P 500 Index ($SPX ) (SPY ) on Thursday closed up +0.77%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.75%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.73%. June E-mini S&P futures (ESM26 ) rose +0.78%, and June E-mini Nasdaq futures...
The nuclear energy start-up is losing a lot of money, burning cash, and issuing shares.
The microreactor maker faces a key deadline.
Oklo Inc. (NYSE:OKLO) is one of the unstoppable AI stocks to buy now. On May 12, Oklo announced a Strategic Partnership Project with Idaho National Laboratory/INL to use the Prometheus AI platform for accelerating advanced reactor and fuel-system designs. This collaboration aims to streamline engineering workflows and technical documentation for the Pluto reactor, an advanced […]
The S&P 500 Index ($SPX ) (SPY ) today is up +0.44%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.49%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.60%. June E-mini S&P futures (ESM26 ) are up +0.40%, and June E-mini Nasdaq futures...
One catalyst could send Oklo shares soaring before July 4.
Oklo (OKLO) is back in focus after filing a new US$1b at-the-market common stock offering, shortly after reporting a first quarter 2026 net loss of US$33.07m and expanding its nuclear project pipeline. See our latest analysis for Oklo. Oklo’s share price has been volatile, with the stock down 5.39% over the last day and 12.51% over the week, yet still showing a 29.14% 1 month share price return and a very large 3 year total shareholder return as investors weigh fresh losses against regulatory...
Oklo just reported a wider-than-expected loss. Is it time to panic?
Siemens Energy, a nuclear play, nearly doubled earnings per share and raised outlook. Siemens stock jumped in a buy zone.
In October 2025, a company with zero revenue, no operating reactors, and a product still years away from commercialization briefly crossed a $30 billion valuation. That company was Oklo Inc. (NYSE: OKLO.
The AI-fueled nuclear rally may have put Oklo in the spotlight, but widening losses and mounting costs are starting to test Wall Street’s patience.
Nuclear reactor startup Oklo updated investors across its three businesses. A July 4 criticality target looms for Oklo and other nuclear stocks.
Oklo (NYSE:OKLO) shares fell about 6% on Wednesday after the advanced nuclear technology company reported a wider first-quarter loss as spending increased to support development of its Aurora powerhouse program and related infrastructure projects. The company posted a Q1 net loss of $33.1...
Jacob Dewitte: Thank you, Sam, and thank you, everyone, for joining us today. It has been almost exactly 2 years since Oklo became a public company. For Oklo, the story has increasingly moved from strategy to execution.
Oklo stock sank on Wednesday after the company said its quarterly loss widened year over year.
Oklo (NYSE:OKLO) reported a wider first-quarter 2026 loss as the advanced nuclear developer said it is moving further into asset deployment across its power, fuel and isotope businesses. Co-founder and Chief Executive Officer Jacob DeWitte told investors that the company has shifted “from strategy
Oklo’s losses deepened in its latest quarter, but the nuclear start-up remains committed to building a first-of-its-kind powerhouse that just cleared a major regulatory hurdle. Oklo finished the quarter with $1.59 billion in cash and cash equivalents and $614.5 million in marketable debt securities. With no revenue to analyze, Oklo’s health is difficult to gauge.
Inflation complicates Fed’s rate plans, Trump’s global tariffs get a reprieve, plastic prices are surging, and more news to start your day.
Oklo’s losses deepened in its latest quarter, but the nuclear start-up remains committed to building a first-of-its-kind powerhouse that just cleared a major regulatory hurdle. Oklo finished the quarter with $1.59 billion in cash and cash equivalents and $614.5 million in marketable debt securities. With no revenue to analyze, Oklo’s health is difficult to gauge.
Oklo Inc (OKLO) reports a net loss while strengthening its balance sheet and advancing key projects in the nuclear sector.
Major U.S. indices closed Tuesday on a mixed note, with the Dow Jones Industrial Average gaining 0.11% to 49,760.55. Meanwhile, the S&P 500 slipped 0.16% to 7,400.96 and the Nasdaq dropped 0.71% to 26,088.20. These are the top stocks that gained the attention of retail traders and investors through the day: Oklo Inc. (NYSE:OKLO) Oklo shares fell 5.76% to close at $73.63, with an intraday high of $76.68 and a low of $70.30. In the after-hours trading, the stock fell 2.89% to $71.50. Oklo reported
Oklo’s losses deepened in its latest quarter, but the nuclear start-up remains committed to building a first-of-its-kind powerhouse that just cleared a major regulatory hurdle. Oklo finished the quarter with $1.59 billion in cash and cash equivalents and $614.5 million in marketable debt securities. With no revenue to analyze, Oklo’s health is difficult to gauge.
Investing.com -- Oklo on Tuesday reported first quarter loss for FY 2026 that was in line with analysts’ estimates as it struggles to translate recent regulatory momentum into commercial progress.